For the quarter ended June 2026, CVRx (CVRX Quick QuoteCVRX - Free Report) reported revenue of $15.71 million, up 15.6% over the same period last year. EPS came in at -$0.53, compared to -$0.57 in the year-ago quarter.

The reported revenue represents a surprise of +0.4% over the Zacks Consensus Estimate of $15.64 million. With the consensus EPS estimate being -$0.52, the EPS surprise was -1.92%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how CVRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Active Implanting Centers: 258 versus the two-analyst average estimate of 266.
• U.S. Revenue Units: 466 versus 463 estimated by two analysts on average.
• Number of Sales Territories in the U.S.: 56 versus the two-analyst average estimate of 59.
• Geographic Revenue- Europe: $0.93 million compared to the $1.27 million average estimate based on two analysts. The reported number represents a change of -28.5% year over year.
• Geographic Revenue- United States: $14.78 million versus the two-analyst average estimate of $14.4 million. The reported number represents a year-over-year change of +21.1%.

View all Key Company Metrics for CVRx here>>>

Shares of CVRx have returned +5.9% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.